Display options
Cite
Santoni M, Paccapelo A, Burattini L, et al. Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncol Lett. 2012;4(4):799-801doi: 10.3892/ol.2012.788.
Santoni, M., Paccapelo, A., Burattini, L., Bianconi, M., Cardinali, M., Fabbietti, L., Trignani, R., Rychlicki, F., & Cascinu, S. (2012). Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncology letters, 4(4), 799-801. https://doi.org/10.3892/ol.2012.788
Santoni, Matteo, et al. "Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study." Oncology letters vol. 4,4 (2012): 799-801. doi: https://doi.org/10.3892/ol.2012.788
Santoni M, Paccapelo A, Burattini L, Bianconi M, Cardinali M, Fabbietti L, Trignani R, Rychlicki F, Cascinu S. Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study. Oncol Lett. 2012 Oct;4(4):799-801. doi: 10.3892/ol.2012.788. Epub 2012 Jul 05. PMID: 23205103; PMCID: PMC3506588.
Copy Download .nbib Format: NLM
Share it on

Oncol Lett. 2012 Oct;4(4):799-801. doi: 10.3892/ol.2012.788. Epub 2012 Jul 05.

Protracted low doses of temozolomide for the treatment of patients with recurrent glioblastoma: A phase II study.

Oncology letters

Matteo Santoni, Alessandro Paccapelo, Luciano Burattini, Maristella Bianconi, Massimo Cardinali, Letizia Fabbietti, Roberto Trignani, Franco Rychlicki, Stefano Cascinu

Affiliations

  1. Department of Medical Oncology.

PMID: 23205103 PMCID: PMC3506588 DOI: 10.3892/ol.2012.788

Abstract

O(6)-alkylguanine-DNA alkyltransferase (AGAT), involved in temozolomide-induced DNA damage repair, plays a key role in the efficacy of temozolomide. AGAT activity may be reduced by protracted temozolomide doses. On the basis of the preclinical findings, we treated patients with a histologically-proven diagnosis of glioblastoma (GBM) following adjuvant temozolomide failure with a low protracted dose of temozolomide (130 mg/m(2)/day, days 1-7 and 15-21, every 4 weeks). The primary endpoint of the study was 6-month progression-free survival (PFS-6 m). The secondary endpoints were overall survival (OS) from the start of temozolomide alternative schedule and toxicity. Enrolment was ceased at 27 patients due to the lack of effectiveness of this regimen. Results indicate that our schedule is well-tolerated, but ineffective in patients with GBM and further strategies are required to improve the outcome of these patients.

References

  1. J Clin Oncol. 2006 Mar 10;24(8):1253-65 - PubMed
  2. Br J Cancer. 2003 Apr 7;88(7):1004-11 - PubMed
  3. J Clin Oncol. 1990 Jul;8(7):1277-80 - PubMed
  4. Biochemistry. 1994 Aug 9;33(31):9045-51 - PubMed
  5. J Clin Oncol. 2007 Aug 1;25(22):3357-61 - PubMed
  6. Oncology. 2010;78(2):103-14 - PubMed
  7. Target Oncol. 2010 Sep;5(3):161-5 - PubMed
  8. Br J Cancer. 2006 Nov 6;95(9):1155-60 - PubMed
  9. N Engl J Med. 2005 Mar 10;352(10):987-96 - PubMed

Publication Types